{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T02:55:28Z","timestamp":1772160928157,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"S2","license":[{"start":{"date-parts":[[2004,6,1]],"date-time":"2004-06-01T00:00:00Z","timestamp":1086048000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2004,6]]},"DOI":"10.1186\/ar1013","type":"journal-article","created":{"date-parts":[[2004,6,24]],"date-time":"2004-06-24T06:22:29Z","timestamp":1088058149000},"source":"Crossref","is-referenced-by-count":22,"title":["Do anti-TNF agents have equal efficacy in patients with rheumatoid arthritis?"],"prefix":"10.1186","volume":"6","author":[{"given":"Sergio","family":"Schwartzman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"G James","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,6,21]]},"reference":[{"key":"1007_CR1","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","volume":"358","author":"DM Lee","year":"2001","unstructured":"Lee DM, Weinblatt ME: Rheumatoid arthritis. Lancet. 2001, 358: 903-911. 10.1016\/S0140-6736(01)06075-5.","journal-title":"Lancet"},{"key":"1007_CR2","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0889-857X(21)00886-3","volume":"16","author":"TD Spector","year":"1990","unstructured":"Spector TD: Rheumatoid arthritis. Rheum Dis Clin North Am. 1990, 16: 513-537.","journal-title":"Rheum Dis Clin North Am"},{"issue":"Suppl 3","key":"1007_CR3","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.1186\/ar578","volume":"4","author":"AJ Silman","year":"2002","unstructured":"Silman AJ, Pearson JE: Epidemiology and genetics of rheumatoid arthritis. Arthritis Res. 2002, 4 (Suppl 3): S265-S272. 10.1186\/ar578.","journal-title":"Arthritis Res"},{"key":"1007_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1136\/ard.61.11.994","volume":"61","author":"TR Mikuls","year":"2002","unstructured":"Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, Cerhan JR: Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis. 2002, 61: 994-999. 10.1136\/ard.61.11.994.","journal-title":"Ann Rheum Dis"},{"key":"1007_CR5","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1136\/ard.61.9.818","volume":"61","author":"HM Lapsley","year":"2002","unstructured":"Lapsley HM, March LM, Tribe KL, Cross MJ, Courtenay BG, Brooks PM: Living with rheumatoid arthritis: expenditures, health status, and social impact on patients. Ann Rheum Dis. 2002, 61: 818-821. 10.1136\/ard.61.9.818.","journal-title":"Ann Rheum Dis"},{"key":"1007_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/art.10148","volume":"46","author":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines","year":"2002","unstructured":"American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis Rheum. 2002, 46: 328-346. 10.1002\/art.10148.","journal-title":"Arthritis Rheum"},{"key":"1007_CR7","first-page":"1423","volume":"28","author":"F Wolfe","year":"2001","unstructured":"Wolfe F, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, Moreland LW, Paulus HE, Pincus T, Russell AS, Wilskie KR: Consensus recommendations for the assessment and treatment of rheumatoid arthritis. J Rheumatol. 2001, 28: 1423-1430.","journal-title":"J Rheumatol"},{"key":"1007_CR8","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/rheumatology\/40.6.699","volume":"40","author":"P Emery","year":"2001","unstructured":"Emery P, Reginster JY, Appelboom T, Breedveld FC, Edelmann E, Kekow J, Malaise M, Mola EM, Montecucco C, Sanda M, Sany J, Scott DL, Serni U, Seydoux G: WHO Collaborating Centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology (Oxford). 2001, 40: 699-702. 10.1093\/rheumatology\/40.6.699.","journal-title":"Rheumatology (Oxford)"},{"key":"1007_CR9","first-page":"891","volume":"30","author":"A Maetzel","year":"2003","unstructured":"Maetzel A, Tugwell P, Boers M, Guillemin F, Coyle D, Drummond M, Wong JB, Gabriel SE: Economic evaluation of programs or interventions in the management of rheumatoid arthritis: defining a consensus-based reference case. J Rheumatol. 2003, 30: 891-896.","journal-title":"J Rheumatol"},{"key":"1007_CR10","first-page":"1","volume":"66","author":"P Emery","year":"2002","unstructured":"Emery P: Is it time for a European consensus on the pharmacological management of early RA?. J Rheumatol Suppl. 2002, 66: 1-2.","journal-title":"J Rheumatol Suppl"},{"key":"1007_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S0167-5699(97)01118-3","volume":"18","author":"A Eigler","year":"1997","unstructured":"Eigler A, Sinha B, Hartmann G, Endres S: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today. 1997, 18: 487-492. 10.1016\/S0167-5699(97)01118-3.","journal-title":"Immunol Today"},{"key":"1007_CR12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1093\/rheumatology\/31.5.293","volume":"31","author":"FM Brennan","year":"1992","unstructured":"Brennan FM, Maini RN, Feldmann M: TNF alpha \u2013 a pivotal role in rheumatoid arthritis?. Br J Rheumatol. 1992, 31: 293-298.","journal-title":"Br J Rheumatol"},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1159\/000237393","volume":"111","author":"M Feldmann","year":"1996","unstructured":"Feldmann M: What is the mechanism of action of anti-tumour necrosis factor-\u03b1 antibody in rheumatoid arthritis?. Int Arch Allergy Immunol. 1996, 111: 362-365.","journal-title":"Int Arch Allergy Immunol"},{"issue":"Suppl 2","key":"1007_CR14","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1186\/ar549","volume":"4","author":"RN Maini","year":"2002","unstructured":"Maini RN, Feldmann M: How does infliximab work in rheumatoid arthritis?. Arthritis Res. 2002, 4 (Suppl 2): S22-S28. 10.1186\/ar549.","journal-title":"Arthritis Res"},{"key":"1007_CR15","first-page":"3504","volume-title":"In Physicians' Desk Reference\u00ae","author":"Medical Economics Company Inc","year":"2002","unstructured":"Medical Economics Company Inc: Prescribing information: Enbrel\u00ae. In Physicians' Desk Reference\u00ae. 2002, Montvale, NJ, 3504-3507."},{"key":"1007_CR16","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1056\/NEJM199707173370301","volume":"337","author":"LW Moreland","year":"1997","unstructured":"Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, Ettlinger RE, Cohen S, Koopman WJ, Mohler K, Widmer MB, Blosch CM: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med. 1997, 337: 141-147. 10.1056\/NEJM199707173370301.","journal-title":"N Engl J Med"},{"key":"1007_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/art.1780360601","volume":"36","author":"DT Felson","year":"1993","unstructured":"Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, Furst D, Goldsmith C, Kieszak S, Lightfoot R, (The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials): The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis Rheum. 1993, 36: 729-740.","journal-title":"Arthritis Rheum"},{"key":"1007_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.7326\/0003-4819-130-6-199903160-00004","volume":"130","author":"LW Moreland","year":"1999","unstructured":"Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleis-chmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Furst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange MLM, McDonnell ND, Weinblatt ME: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999, 130: 478-486.","journal-title":"Ann Intern Med"},{"key":"1007_CR19","volume-title":"Presented at the 2nd Annual European Congress of Rheumatology (EULAR)","author":"LW Moreland","year":"2001","unstructured":"Moreland LW, Cohen SB, Baumgartner SW, Schiff MH, Tindall EA, Burge DJ: Long-term use of Enbrel\u00ae (etanercept) in patients with DMARD-refractory rheumatoid arthritis. Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001."},{"key":"1007_CR20","volume-title":"Presented at the 3rd Annual European Congress of Rheumatology (EULAR)","author":"LW Moreland","year":"2002","unstructured":"Moreland LW, Cohen S, Fleischmann RM, Baumgartner SW, Schiff MH, Burge DJ: Safety and efficacy of up to 5 years of etanercept (Enbrel\u00ae) therapy in rheumatoid arthritis. Presented at the 3rd Annual European Congress of Rheumatology (EULAR). 2002, , Stockholm, Sweden, on 14 June 2002."},{"key":"1007_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999, 340: 253-259. 10.1056\/NEJM199901283400401.","journal-title":"N Engl J Med"},{"key":"1007_CR22","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/art.11142","volume":"48","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Weinblatt ME, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Jackson CG, Atkins KM, Feng A, Burge DJ: Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. Arthritis Rheum. 2003, 48: 1493-1499. 10.1002\/art.11142.","journal-title":"Arthritis Rheum"},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1056\/NEJM200011303432201","volume":"343","author":"JM Bathon","year":"2000","unstructured":"Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000, 343: 1586-1593. 10.1056\/NEJM200011303432201.","journal-title":"N Engl J Med"},{"key":"1007_CR24","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1002\/art.10308","volume":"46","author":"MC Genovese","year":"2002","unstructured":"Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002, 46: 1443-1450. 10.1002\/art.10308.","journal-title":"Arthritis Rheum"},{"key":"1007_CR25","first-page":"1808","volume":"21","author":"MJ Plant","year":"1994","unstructured":"Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT: Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol. 1994, 21: 1808-1813.","journal-title":"J Rheumatol"},{"key":"1007_CR26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0033-8389(22)00465-1","volume":"34","author":"JT Sharp","year":"1996","unstructured":"Sharp JT: Scoring radiographic abnormalities in rheumatoid arthritis. Radiol Clin North Am. 1996, 34: 233-241.","journal-title":"Radiol Clin North Am"},{"key":"1007_CR27","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1002\/art.10181","volume":"47","author":"D Van Der Heijde","year":"2002","unstructured":"Van Der Heijde D, Simon L, Smolen J, Strand V, Sharp J, Boers M, Breedveld F, Weisman M, Weinblatt M, Rau R, Lipsky P: How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion. Arthritis Rheum. 2002, 47: 215-218. 10.1002\/art.10181.","journal-title":"Arthritis Rheum"},{"key":"1007_CR28","volume-title":"Presented at the 2nd Annual European Congress of Rheumatology (EULAR)","author":"M Genovese","year":"2001","unstructured":"Genovese M, Martin RW, Fleischmann R, Keystone E, Bathon J, Spencer-Green G, Finck B: Enbrel\u00ae (etanercept) vs. methotrexate (MTX) in early rheumatoid arthritis (ERA trial): two-year follow up. Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 16 June 2001."},{"key":"1007_CR29","first-page":"557","volume":"20","author":"GA Wells","year":"1993","unstructured":"Wells GA, Tugwell P, Kraag GR, Baker PRA, Groh J, Redelmeier DA: Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993, 20: 557-560.","journal-title":"J Rheumatol"},{"key":"1007_CR30","volume-title":"Presented at the 2nd Annual European Congress of Rheumatology (EULAR)","author":"R Fleischmann","year":"2001","unstructured":"Fleischmann R, Baumgartner S, Moreland L, Schiff M, Markenson J, Spencer-Green G: Improvement of disability in RA patients with early vs established disease after treatment with Enbrel\u00ae (etanercept). Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001."},{"key":"1007_CR31","volume-title":"Humira: package insert","author":"Abbott Laboratories","year":"2002","unstructured":"Abbott Laboratories: Humira: package insert. 2002, Abbott Park, IL"},{"key":"1007_CR32","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1136\/ard.2003.009563","volume":"62","author":"LBA de Putte","year":"2003","unstructured":"de Putte LBA, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PLCM, Schattenkirchner M, Emery P, Burmester GR, Zeidler H, Montsopoulos HM, Beck K, Kupper H: Efficacy and safety of the fully human anti-tumour necrosis factor \u03b1 monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. Ann Rheum Dis. 2003, 62: 1168-1177. 10.1136\/ard.2003.009563.","journal-title":"Ann Rheum Dis"},{"key":"1007_CR33","volume-title":"Presented at the 2nd Annual European Congress of Rheumatology (EULAR)","author":"E Keystone","year":"2001","unstructured":"Keystone E, Weinblatt ME, Weisman M, Furst D, Paulus H, Birbara C, Fischkoff S, Chartash EK: The fully human anti-TNF monoclonal antibody, adalimumab (D2E7), dose ranging study: the 24-week clinical results in patients with active RA on methotrexate (the ARMADA trial). Presented at the 2nd Annual European Congress of Rheumatology (EULAR). 2001, , Prague, the Czech Republic, on 15 June 2001."},{"key":"1007_CR34","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/art.10697","volume":"48","author":"ME Weinblatt","year":"2003","unstructured":"Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, Teoh LA, Fischkoff SA, Chartash EK: Adalimumab, a fully human anti-tumor necrosis factor alpha mono-clonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. 2003, 48: 35-45. 10.1002\/art.10697.","journal-title":"Arthritis Rheum"},{"key":"1007_CR35","volume-title":"Presented at the 3rd Annual European Congress of Rheumatology (EULAR)","author":"AF Kavanaugh","year":"2002","unstructured":"Kavanaugh AF, Weinblatt M, Keystone E, Furst DE, Moreland LW, Teoh L, Fischkoff S, Chartash E: The ARMADA trial: 12-month efficacy and safety of combination therapy with adalimumab (D2E7), the first fully human anti-TNF monoclonal antibody, and methotrexate (MTX) in patients with active rheumatoid arthritis. Presented at the 3rd Annual European Congress of Rheumatology (EULAR). 2002, , Stockholm, Sweden, on 14 June 2002."},{"issue":"9 Suppl","key":"1007_CR36","first-page":"S205","volume":"46","author":"E Keystone","year":"2002","unstructured":"Keystone E, Kavanaugh AF, Sharp J, Hua Y, Teoh L, Fischkoff S, Chartash E: Adalimumab (D2E7), a fully human anti-TNF-\u03b1 monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy. Arthritis Rheum. 2002, 46 (9 Suppl): S205-","journal-title":"Arthritis Rheum"},{"key":"1007_CR37","volume-title":"Remicade: package insert, revised June 2002","author":"Centocor, Inc.","year":"2002","unstructured":"Centocor, Inc.: Remicade: package insert, revised June 2002. 2002, Malvern, PA"},{"key":"1007_CR38","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1124\/jpet.301.2.418","volume":"301","author":"B Scallon","year":"2002","unstructured":"Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, Wagner C: Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002, 301: 418-426. 10.1124\/jpet.301.2.418.","journal-title":"J Pharmacol Exp Ther"},{"key":"1007_CR39","doi-asserted-by":"publisher","first-page":"1932","DOI":"10.1016\/S0140-6736(99)05246-0","volume":"354","author":"R Maini","year":"1999","unstructured":"Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P, for the ATTRACT Study Group: Infliximab (chimeric anti-tumour necrosis factor \u03b1 monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet. 1999, 354: 1932-1939. 10.1016\/S0140-6736(99)05246-0.","journal-title":"Lancet"},{"key":"1007_CR40","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","volume":"343","author":"PE Lipsky","year":"2000","unstructured":"Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN, for the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group: Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med. 2000, 343: 1594-1602. 10.1056\/NEJM200011303432202.","journal-title":"N Engl J Med"},{"issue":"Suppl 9","key":"1007_CR41","first-page":"1216","volume":"43","author":"P Lipsky","year":"2000","unstructured":"Lipsky P, van der Heijde D, St Clair W, Furst D, Kalden J, Weisman M, Breedveld F, Emery P, Keystone E, Harriman G, Maini R: The ATTRACT Investigators. 102-week clinical and radiologic results from the ATTRACT trial: a 2-year, randomized, controlled, phase 3 trial of infliximab (Remicade\u00ae) in patients with active RA despite MTX. Arthritis Rheum. 2000, 43 (Suppl 9): 1216-","journal-title":"Arthritis Rheum"},{"key":"1007_CR42","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan FM, Walker J, Bijl H, Ghrayeb J, Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor \u03b1. Arthritis Rheum. 1993, 36: 1681-1690.","journal-title":"Arthritis Rheum"},{"key":"1007_CR43","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/S0140-6736(94)90632-7","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Bijl H, Woody JN: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet. 1994, 344: 1125-1127. 10.1016\/S0140-6736(94)90632-7.","journal-title":"Lancet"},{"key":"1007_CR44","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1016\/S0140-6736(94)90628-9","volume":"344","author":"MJ Elliott","year":"1994","unstructured":"Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor \u03b1 (cA2) versus placebo in rheumatoid arthritis. Lancet. 1994, 344: 1105-1110. 10.1016\/S0140-6736(94)90628-9.","journal-title":"Lancet"},{"key":"1007_CR45","first-page":"841","volume":"27","author":"A Kavanaugh","year":"2000","unstructured":"Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P: Chimeric anti-tumor necrosis factor-\u03b1 monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000, 27: 841-850.","journal-title":"J Rheumatol"},{"key":"1007_CR46","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W","volume":"41","author":"RN Maini","year":"1998","unstructured":"Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfar-lane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor \u03b1 monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998, 41: 1552-1563. 10.1002\/1529-0131(199803)41:3<565::AID-ART28>3.3.CO;2-#.","journal-title":"Arthritis Rheum"},{"key":"1007_CR47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2165\/00019053-199406060-00005","volume":"6","author":"SH Allaire","year":"1994","unstructured":"Allaire SH, Prashker MJ, Meenan RF: The costs of rheumatoid arthritis. Pharmacoeconomics. 1994, 6: 513-522.","journal-title":"Pharmacoeconomics"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/ar1013\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/ar1013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T22:14:43Z","timestamp":1682720083000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/ar1013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6]]},"references-count":47,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2004,6]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1186\/ar1013","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6]]},"article-number":"S3"}}